Company profile: Orca Bio
1.1 - Company Overview
Company description
- Provider of clinical-stage, high-precision cell therapies dedicated to delivering curative medicine. Products include Orca-T, which replaces a patient's diseased blood and immune system with a healthy one while reducing the risk of GvHD and other side effects, and Orca-Q, for patients with haploidentical donors, designed to offer therapeutic benefits while minimizing the risk of acute and chronic GvHD.
Products and services
- Clinical-Stage Cell Therapy Development: Clinical-stage program that architects and advances cell therapies dedicated to delivering curative medicine to patients
- Orca-Q: Haploidentical-compatible cell therapy that delivers therapeutic benefits to patients with haploidentical donors while minimizing the risk of acute and chronic GvHD
- Orca-T: High-precision cell therapy that replaces a patient's diseased blood and immune system with a healthy one, reducing the risk of GvHD and other side effects
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Orca Bio
Gossamer Bio
HQ: United States
Website
- Description: Provider of biopharmaceutical discovery and development of novel and differentiated therapeutic products, including seralutinib for pulmonary arterial hypertension in Phase 3 clinical trials, and offering clinical trials and an expanded access program for investigational medicines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gossamer Bio company profile →
Septerna
HQ: United States
Website
- Description: Provider of GPCR-focused drug discovery platforms and services, including a Native Complex Platform that reproduces receptors outside cells, enabling discovery for previously undruggable GPCRs; GPCR affinity screening; structural biology using cryo-EM; and in silico screening, plus small-molecule discovery programs targeting well-validated GPCRs across multiple therapeutic areas.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Septerna company profile →
Receptos
HQ: United States
Website
- Description: Provider of drug discovery, development and commercialization of therapeutics for immune disorders, leveraging pioneering G protein-coupled receptor (GPCR) technology to facilitate information-driven drug design for best- and first-in-class drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Receptos company profile →
Talaris Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology engaged in developing innovative cellular therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Talaris Therapeutics company profile →
TRex Bio
HQ: United States
Website
- Description: Provider of a deep biology platform that maps human tissue regulatory T cell behavior to disease using high-resolution sequencing, computational biology and translational assays to identify targets, and developer of therapeutics for cancer, fibrotic and immune-mediated diseases, including TRB-061 (TNFR2 agonist; IND-enabling, FIH 2025), TRB-031/-041 (with Eli Lilly; lead optimization) and TRB-071/-081 (target ID/validation).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TRex Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Orca Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Orca Bio
2.2 - Growth funds investing in similar companies to Orca Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Orca Bio
4.2 - Public trading comparable groups for Orca Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →